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Introduction. RVI (rotavirus infection) is the most common cause of dehydration in in-
fants and young children. The implementation of the sentinel surveillance of RVI in infants 
from 2008 in the Republic of Moldova demonstrated the high rate of this infection 
(40.0%), being an argument in recommending the antirotaviral immunization in children 
within the National Immunization Program. 
Material and methods. The study enrolled 193 children with acute diarrheal disease, 
included in the sentinel supervision (2012-2016) and treated in the Unit for Acute Diar-
rheal Diseases at Children’s Clinical Hospital no. 1. The biological material was examined 
by serological enzyme-linked immunosorbent assay (ELISA) and genotyping, revealed by 
polymerase chain reaction (PCR).  
Results. The rotavirus infection was confirmed in 193 infants, of which 121 children were 
not vaccinated against RVI, and 72 were immunized. Depending on the genotypes encoun-
tered before and after vaccination, it was found that G9P [8], G3P[8], G4P[8] were de-
tected before vaccination, although postvaccine prevailed G2P[4], G4P[8]. In addition, the 
incidence of RVI is decreasing and the disease evolution is much better. 
Conclusions. This article reflects the evolution of the genotypic properties of rotaviruses 
and the clinical-paraclinical particularities of RVI in infants, highlighting the importance 
of the implementation of antiretroviral immunization in children within the National Im-






EVALUAREA COMPARATIVĂ A MANIFESTĂRILOR CLINICO-PARACLINICE ALE     
INFECȚIEI ROTAVIRALE VERSUS VARIETATEA GENOTIPICĂ LA SUGARI 
Introducere. IRV (infecţie rotavirală) este cauza cea mai frecventă de deshidratare la 
sugar şi la copilul mic. Implementarea în Republica Moldova în anul 2008 anul 2008 a 
supravegherii santinelă a IRV la sugari a relevat o rata înaltă a infecţiei (40,0%), acest 
fapt servind ca argument în recomandarea imunizării antirotavirale a copiilor în cadrul 
Programului Naţional de Imunizări. 
Material şi metode. În studiu au fost incluşi 193 de copii sugari cu boală diareică acută, 
aflați sub supravegherea santinelă în perioada 2012-2016 şi trataţi în Secţia de boli 
diareice acute a Spitalului Clinic Municipal de Copii nr. 1. Materialul biologic s-a examinat 
prin metoda reacţiei serologice ELISA, iar evidenţierea genotipurilor a fost efectuată prin 
reacţia de amplificare genică PCR.  
Rezultate. Dintre cei 193 de sugari cu infecţie rotavirală, 121 nu au fost vaccinaţi contra 
IRV, iar 72 – au fost imunizaţi. În funcţie de genotipurile întâlnite până şi după vaccinare, 
s-a constatat că până la vaccinare au predominat genotipurile G9P[8], G3P[8], G4P[8]. În 
schimb, postvaccinal au prevalat genotipurile G2P[4], G4P[8], incidenţa IRV fiind în 
scădere, iar evoluţia bolii – mult mai uşoară.  
Concluzii. Acest articol reflectă evoluţia proprietăţilor genotipice ale rotavirusurilor şi a 
particularităţilor clinico-paraclinice ale IRV la sugari, cu o importanţă majoră în contex-
tual procesului de implementare a imunizării antirotavirale a copiilor în cadrul Pro-
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Rotaviruses (RV) are one of the most common 
causes of acute gastroenteritis (AGE) worldwide, 
affecting 95.0% of children up to the age of five. 
Globally, it is estimated that RV infection causes 
3.6 million episodes of AGE per year (1, 2). By the 
time antirotaviral immunization was imple-
mented, more than 2 million children with GEA of 
rotavirus etiology were hospitalized annually 
worldwide (2, 3). 
By the age of 5, almost all children have suffered 
from rotavirus infection (RVI), which is the first 
cause of severe diarrhea with dehydration in in-
fants worldwide. In low-income countries, the av-
erage age of primary infection with rotaviruses 
occurs between 6 and 9 months (80.0% of cases 
occur in infants under 1 year), whereas in high-
income countries the first episode sometimes oc-
curs at the age of 2-5 years, children being the 
most affected (65.0% of cases being found in in-
fants) (3, 4). 
Despite considerable progress, diarrheal disease 
remains the fourth most common cause of mor-
tality and the second most common cause of mor-
bidity worldwide in children younger than 5 
years. Rotaviruses are associated with approxi-
mately one third of all severe diarrheal diseases 
in young children, with recent estimates of annual 
mortality associated with rotaviruses ranging 
from 453,000 (2008), 197,000 (2010) and 
173,000 (2011) (1, 3). 
Since 2009, the World Health Organization 
(WHO) has recommended that rotavirus vaccines 
be included in national immunization programs 
in each country and that this measure be consid-
ered a public health priority (5, 6). 
Globally, rotavirus is the most common cause of 
severe gastroenteritis in children<5 years of age, 
accounting for an estimated 2.4 million hospital 
admissions and 527,000 deaths each year (1,7). 
Because of the tremendous global burden of rota-
virus, vaccine development and introduction has 
been a high priority for several international 
agencies, including the World Health Organiza-
tion (WHO) and the Global Alliance for Vaccines 
and Immunization (GAVI) (8). 
The assessment of morbidity in children under 
one year of age marks an increased incidence of 
the most commonly encountered infections, 
which determines the formation of a healthy soci 
ety and of future generations. In acute gastroen-
teritis, primary rotaviruses are acquired through 
contact with the diseased being (1, 4, 9). Rota-
viruses are also detected in the co-filters of chil-
dren with gastroenterocolitis of indetermi-nate 
etiology, having the primary role in identifying se-
rious gastrointestinal infections, with etiology 
difficult to establish (5, 8, 10). 
The problem of rotavirus infection remains cur-
rent during the last decades, since the discovery 
of this virus, the rotavirus infection being present 
with an increased incidence, especially among 
children under 5 years (11, 12). Each child can 
withstand from one disease episode to several ep-
isodes, most commonly in the first 5 years of life, 
characterized by a high incidence of serious cases, 
with complications, in the absence of therapy. The 
clinical impact in rotavirus infection is with intes-
tinal and non-intestinal disorders, involving not 
only the lining of the gastrointestinal tract, but 
also of other systems. In infants, the severity of ro-
tavirus infection is determined in particular by 
the genotype and phenotype of this condition, 
which determines the severity of dehydration and 
toxic syndrome (12, 13). 
 
MATERIAL AND METHODS 
This present prospective, descriptive study in-
cluded 193 children with acute diarrheal disease, 
involved in the sentinel surveillance (2012-2016) 
from the Acute diarrheal diseases unit, at the Mu-
nicipal Children’s Clinical Hospital no. 1. 
The research protocol was approved by the Re-
search Ethics Committee of the Nicolae Testemi-
tanu SUMPh from the Republic of Moldova (re-
port no. 54 of 13.02.2017).  
All patients were selected according to the stand-
ard case scenario. The hospitalization rules and 
the completion of a standardized questionnaire 
for this study were respected. The parents of the 
children gave written informed consent for their 
enrollment in the research. 
The criteria for inclusion in the study were as fol-
lowing: 
1. Children aged between 1 - 12 months (ac-
cording to WHO recommendations); 
2. diarrhea with at least 3 defecations over 
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3. patients examined by serological reaction 
ELISA with genotypes detected in PCR for ro-
tavirus infection within the first 24 hours af-
ter admission; 
The criteria for exclusion of patients from re-
search: 
1. patients with rotavirus infection or severe 
comorbidities (heart defects, digestive tract 
development abnormalities, nervous system 
development abnormalities etc.). 
2. patients with diarrhea of less than 3 fluid 
defecations over the last 24 hours. 
3. children aged over 12 months. 
The assessment regarding signs of dehydration 
was performed in children included in the study 
at the time of clinical examination. The biological 
material of all the children included in the study 
was virologically examined for rotavirus infec-
tion, using the ELISA serological reaction and gen-
otyping in the chain polymerization reaction 
(ProSpecT ROTAVIRUS Kit, manufacturer – 
Zhejiang Orient Gene Biotech Co. LTD, China).  
This is a qualitative immunoenzymatic test for the 
detection of rotavirus (group A) in human faecal 
samples, which help in diagnosing acute gastro-
enteritis. The assay uses a polyclonal antibody to 
detect group-specific proteins, including the main 
internal capsid protein (VP6), present in A rota-
viruses (13). 
About 1.5-2 ml of liquid faeces or 1 g of fresh 
semi-formed fa eces, spontaneously excreted 
were collected in a sterile recipient from each pa-
tient on the first day of hospitalization. The con-
tainer was hermetically sealed, labelled with pa-
tient data and stored at 2-8˚C until being trans-
ported. Also, each patient positive for rotavirus 
infection, was established on the vaccine status, 
by questioning the caregiver with whom the child 
was admitted to the hospital, checking the child’s 
development booklet and checking the vaccina-
tion register at the residence place.  
Depending on the vaccine status, the study sam-
ple (n=193) was divided into group “Unvac-
cinated children with rotavirus infection” (n=121) 
and group “Vaccinated children with rotavirus in-
fection” (n=72). 





Po – according to the bibliographic data (11), the 
success of the treatment in the unvaccinated pa-
tients constitutes on average 50.0% (P0=0.50); 
P1 – expected success of treatment in the vac-
cinated children group will be 75.0% 
(P1=0.75); P=(P0+P1)/2=0.625; 
Zα – table value, when the statistical signifi-
cance is 95.0%, then the coefficient Zα=1.96; 
Zβ – table value, when the statistical power of 
the comparison is 80.0%, then the coefficient 
Zβ=0.84; 
f – Proportion of subjects expected to abandon 
the study for reasons other than the investi-
gated effect q=1/(1-ƒ), ƒ=10.0% (0.1). 
 
Therefore, the L1 research group included no less 
than 65 patients vaccinated against rotavirus in-
fection and the L0 control group included no less 
than 65 unvaccinated patients. 
The data collected in the study were introduced 
into the electronic table via the Microsoft Office 
Excel 2007 program. The results were processed 
using the SPSS version 22 software. For compar-
ing the differences between groups, the 95% con-
fidence interval (95CI), the criterion (csi-square) 




In both groups, male sex prevailed. Depending on 
age, children aged 6-12 months from the unvac-
cinated group predominated in 66.9% cases, com-
pared to the vaccinated group, where this age 
group constituted only 47.2%. 
The patients included in the study were admitted 
to the hospi  tal during the first 3 days of illness. 
In all patients, the disease started with acute in-
toxication syndrome in 100% of cases in unvac-
cinated children compared with 82% in vac-
cinated children, characterized by alteration of 
the overall health condition, decreased appetite 
and malaise.  
Table 1 shows a much more severe evolution of 
the unvaccinated children who suffered from ro-
tavirus infection, compared with the vaccinated 
ones, thus moderate and severe dehydration ac-
counted for 53.7% vs. 30.6% in the vaccinated 
group. The clinical form in which rotavirus infec-
tion occurred was manifested by gastroenterocol-
itis in 81% of unvaccinated and 75% of those vac-
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Abs, % Abs. % 
Acute gastroenterocolitis, without dehydration 37(30.6) 36(50.0) 7.186 0.0073 
Acute gastroenterocolitis, moderate dehydration  56(46.4)  17(23.6) 9.919 0.0016 
Acute gastroenterocolitis, severe dehydration  5(4.1) 1(1.4) 1.092 0.2960 
Acute enterocolitis, without dehydration  19(1.,7) 14(19.4) 0.434 0.5100 
Acute enterocolitis, moderate dehydration  4(3.3) 4(5.6) 0.596 0.4401 
Note: statistical test applied: χ2.        
 
Unvaccinated children presented vomiting in 
80% of cases, fever – in 76.9%, faces with 
pathological inclusions – in 97.5%, whereas vac-
cinated children showed less frequent symptoms 
(tab. 2). 
 





Vaccinated (n=72) X2 P 
Vomiting 98 (80%) 50 (69.4%)     1.821 0.0686 
Fever 93 (76.9%) 54 (75%) 0.293 0.7694 
Liquid feces 121 (100%) 72 (100%) 1.245 0.2133 
Feces with mucus 115 (95%) 60 (83.3%) 2.561 0.0104 
Feces with foam 3 (2.5%) 0 0.957 0.3383 
Note: statistical test applied: χ2. 
 
Table 3 shows the frequency of comorbidities that 
occurred concurrently with rotavirus infection. 
The incidence of the respiratory system diseases 
was higher, accounting for 61.1% of cases, fol-
lowed by GI disorders - 57.8%, whereas the NS 
impairment ranked third among these. 
 
Table 3. Structure of comorbidities in study groups in children 
 with acute diarrheal disease of rotavirus etiology. 
 






Respiratory diseases (bronchitis, pneumo-
nia) 
74 (61.1%) 38 (52.7%) 1.300 0.2541 
GI disorders 70 (57.8%) 27 (37.5%) 7.402 0.0065 
Nervous system diseases (HIPE, TIE) 48 (40%) 6 (8.3%) 22.299 0.0001 
The reno-urinary system pathoogies (UTI) 27 (22.3%) 10 (13.8%) 2.097 0.1476 
Hematopoietic system disorders (anemia) 27 (22.3%) 12 (16.6%) 0.906 0.3412 
Allergic dermatitis  9 (7.4%) 6 (8.3%) 0.051 0.8214 
Malnutrition  7 (5.7%) 2 (2.8%) 0.857 0.3545 
ENT diseases  11 (9%) 1 (1.4%) 4.484 0.0342 
Note: statistical test applied: χ2. HIPE – hypoxiischemic perinatal encephalopathy; TIE – toxi-infectious encepha-
lopathy; UTI – urinary tract infections. 
 
The hospital stay of most unvaccinated children 
was doubled compared to the vaccinated ones. 
Thus, the mean length of hospitalization of unvac-
cinated children was 6.7 days, whereas vac-
cinated children had a mean hospital stay of 6 
days (fig. 1). 
The rotavirus etiology of acute diarrheal disease 
was confirmed in all patients included in the 
study. 73.6% of cases of acute diarrheal disease of 
viral etiology was associated with bacterial flora, 
more significantly in unvaccinated children. Thus, 
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and Proteus mirabilis predominated in 5.0% of 
patients, double compared with the vaccinated 
group, followed by Staphylococcus aureus and 
Citrobacter freundii, accounting for 4%. Atypical 
h+ Escherіchіa colі and Klebsiella oxytoca were 
detected in 2.5% of children. The etiological 




Figure 1. The RVI severity depending on the hospital stay length within both study groups. 
 
 
Table 4. Bacterial over infection of children affected by rotavirus infection. 
 
Infection Unvaccinated Vaccinated X2 P 
Rotaviral mono-infection  84 (69.4%) 53 (73.6%) 0.620 0.5354 
Bacterial association (total) 37 (30.6%) 19 (26.4%) 0.620 0.5354 
Staphylococcus aureus 
St. aureus associated with other gram (+) bacteria  
Klebsiella pneumoniae şi oxytoca 
Klebsiella associated with other gram (+) bacteria 
Escherіchіa coli 
Proteus vulgaris şi mirabilis 





























Note: The assessment was based on Fisher's exact test. 
 
The present study identified acetonuria in 47 un-
vaccinated children vs. 20 vaccinated children. 
Thus, a high amount of ketone bodies in the urine 
(≥150 mg/dl) was found in 21.3% of the cases 
among unvaccinated children, compared with 5% 
in children from the vaccinated group. 
Of the total number of genotypes samples, the in-
cidence of genotypes identified in patients with 
rotavirus infection during the prevaccine period, 
the most commonly encountered genotypes were 
G4P[8], G3P[8] and G9P[8]. In the postvaccine pe-
riod, their frequency decreased first, being the 
genotypes G2P[4] and G4P[8] (fig. 2). 
 
DISCUSSIONS 
Rotavirus is one of the most important causative 
agents of acute dehydrating diarrheal disease, be- 
ing involved in 12.0-71.0% of acute hospi-talized 
gastroenteritis cases. In developed countries ro-
taviruses cause from 1/3 to 1/2 of all serious di-
arrhea. Thus, about 3 million cases of rotavirus in-
fection (RVI) are registered annually in the USA, 
which causes 67 thousand hospitalizations (250 
thousand day/bed) and more than 100 cases of 
deaths (14). 
In 2006, two live attenuated vaccines were deve-
loped and authorized: Rotarix® and RotaTeq®. Ro-
tarix is a monovalent vaccine derived from a hu-
man G1P isolate [8]. RotaTeq® is a pentavalent, 
consisting of a mixture of monoreassortants hu-
man bovine rotavirus, which transports genes en-
coding human G1, G2, G3, G4 and P[8] proteins 
into a genetic background of Wi79 bovine rota-
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Both vaccines have proven to be very effective in 
clinical trials and have been included in the man-
datory national vaccination scheme for children 
in over 100 countries since 2006. Post-marketing 
studies have shown that both vaccines are highly 
effective at the population level (7, 15, 16). 
 
 
Figure 2. The evolution of the frequency of genotype incidence among RVI patients before and 
after vaccination (%). 
 
Moldova was the first country in the WHO Euro-
pean Region to introduce rotavirus vaccination 
into the routine immunization program for chil-
dren. The vaccine used in Moldova includes G4, 
G2, G9 genotypes that cover most strains of circu-
lating rotaviruses in the population of the country 
according to the monitoring and sentinel surveil-
lance data in children up to the age of 5 years. 
In their study, Codruţa Iliescu Haliţchi et al. 
(2013), also noted that most cases (85.0%) oc-
curred between January and July, with 2 peaks in 
February (25.7%) and June (21.4%) (15). 
The study performed by Stela Gheorghita high-
lighted the favorable impact of the vaccination 
program on rotavirus disease among children 
from Chisinau, Moldova. Two-dose rotavirus vac-
cination reduced hospitalization by 79%, and se-
vere disease progression was reduced by 82%. 
Generally, hospitalizations with rotavirus de-
creased by two-thirds until the second year of the 
program, in a model compatible with the impact 
of the vaccine. The major decrease was among 
vaccinated cohorts children <1 year in the first 
year and <2 years in the second year after vaccine 
implementation. In  
addition, the number of children <5 years old hos-
pitalized with rotavirus decreased significantly, 
including unvaccinated cohorts, suggesting indi-
rect protection resulting from children’s immun-
ization (17).  
According to our data, this is the first research 
study of patients with rotavirus infection, follow-
ing the vaccination program in the Republic of 
Moldova, which analyzed the prophylactic poten-
tial of the antirotaviral vaccine in our country. 
Given that vaccines have been very effective in 
high-income countries, they have proven to be 
considerably less powerful in low- and middle-in-
come countries. The disease associated with rota-
virus was the cause of death in more than 200,000 
children aged <5 years worldwide in 2013. 
A long-term study was carried out by Joshua 
Gikonyo et al., lasting from January 2015 until De-
cember 2017. Patients with rotavirus gastroen-
teritis were supervised within in several hospitals 
in Kenya. The subjects of the study were infants 
and young children under 5 years of age, who had 
an episode with three liquid or watery stools for 
24 hours for up to 7 days, with or without epi-
sodes of vomiting. In this study, the distribution 
of cases of rotavirus infection during the year was 
more frequently recorded in August-September, 
with a reduction in the number of cases in Novem-
ber-January (18). 
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According to Ulrich Desselberger, vaccine effect-
tiveness was higher in high-income countries, 
with severe rotavirus disease protection rates at 
80-90%, whereas in low- and middle-income 
countries it was 30-50% lower. Different factors 
were assessed to identify or suggest the differ-
ences in efficacy of the rotavirus vaccine, includ-
ing malnutrition, intestinal microbiota status, vit-
amin D3 administration, co-infections, immunity 
of the infant immune system and genetic factors 
(19). 
Raúl F. Velázquez performed a systematic review 
and metaanalysis to describe, compare and syn-
thesize the effectiveness of the vaccine, from ran-
domized clinical trials prior to authorization, 
finding a decrease in hospitalizations and ad-
dresses to the children’s emergency depar-tment 
with rotavirus infections (20). 
Alkali B. R. et al, in 2015 conducted a pediatric 
study on a sample of 200 children with diarrhea. 
Of these, 51 (25.5%) children were positive for 
rotavirus. Among children with rotavirus infec-
tion, 79.1% of cases had watery stools and 75.0% 
– semi-liquid stools.  Short-term diarrhea lasted 2 
days in most cases (43.1%), the liquid stool lasted 
7 days in 27.5%, and only in 2.0% it lasted 10 
days. 40 children out of 51 had vomiting that oc-
curred in the first two days of illness, accounting 
for 90.0%, on the 7th day it was found in only 
7.5% of children. Chi-square analysis indicated a 
significant association between rotavirus diar-
rhea and vomiting (P<0.05) (16, 21). 
28 studies from 12 countries included data on the 
proportion of GERV among hospitalized children 
under the age of five in the Middle East and North 
Africa. These studies included 17,233 cases of di-
arrhea that were tested for rotavirus infection. Of 
these, 7,366 (42.7%) were RV positive. Depen-
ding on the country, the average share of cases 
with rotaviral infection ranged from 316 (22.5%) 
to 1,885 cases (63%). Egypt, Tunisia and the Is-
lamic Republic of Iran reported the lowest pro-
portion with 316 (22.5%), 65 (23.3%) and 537  
cases (27.4%). The highest proportion was ob-
served in Turkey 1,885 (63%), the United Arab 
Emirates 381 (50.3%), and Saudi Arabia 1,226 
cases (48.7%). The other countries reported a 
percentage between 93 (35.8%) and 358 cases 
(45.2%) (22). 
Another study carried out in the neighboring 
country Romania (2014) by Victoria Birlutiu and 
Rares Mircea Birlutiu between January 1, 2011 – 
December 31, 2012, aimed at tracking the season-
ality of the disease, the clinical aspects, the sever-
ity of the disease, the laboratory examina-tions, 
the need for parenteral rebalancing, the costs of 
hospitalization. The study group consisted of 236 
children (2011 – 114 cases, 2012 – 122 cases) be-
tween 0 and 16 years old with rotavirus infection 
in the infectious diseases services in children in 
Sibiu. Thus, 114 cases were diagnosed in 2011, re-
spectively 122 in 2012, commonly in the cold 
months, more frequently in the male gender, sex 
ratio M/F 1.42:1 in 2011, 1.18:1 in 2012, among 
children aged 1-3 years – 58.90%. 91 cases in 
2011 – 79.82%, and 112 cases in 2012 – 91.80% 
respectively, with an average / severe score. 15 
cases showed neurological disorders and 15 cases 
acute renal failure. Severe onset cases led to hos-
pitalization in the first 24 hours: 41.23% of cases 
in 2011 and 51.64% in 2012, prolonged with di-
arrhea over 6 days, established in 62 cases 
(54.39%) in 2011 and 75 cases (61.48%) in 2012. 
Cases with severe dehydration were found in chil-
dren aged 1 to 12 months, being associated with 
thrombocyte-penia, leukopenia, PCR increase 
(probability 0.42), hydroelectrolyte imbalances 
associated with signs of encephalo-pathy. This 
study highlighted the frequent association of hy-
ponatremia (<130 mEq/l) from electrolyte imbal-
ance with rotavirus gastroenteritis, 83 cases in 
2011 and 51 cases in 2012. Therefore, it is worth 
mentioning that in Romania the rotavirus vaccine 
was not included in National Immunization Pro-
gram (7, 21).   
Estimation of 2-dose vaccine effectiveness in Mol-
dova, especially against severe cases at 84% 
(95CI: 65% to 93%), is largely compatible with 
that in other countries with low mortality (in the 
mortality layers A and B of WHO), namely VE is 
85% (95CI: 80% to 88%) based on the overall 
analysis of 8 studies, including >32,000 partici-
pants (17, 22). 
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1. The clinical and etiological evolution of rotavirus infection was presented by the following genotypes: 
G4P[8], G9P[8], G2P[4] and G3P[8]. The peak incidence of rotavirus infection being in February, more 
commonly found in boys over 6 months. 
2. The polymorphism of the clinical manifestations in the rotavirus infection identified in the study 
groups, showed a severe and extremely severe evolution of the entity among unvaccinated children, 
which was 2.85 times higher than in the group of vaccinated ones (p<0.005). 
3. Stool test indices in unvaccinated children exhibited a massive inflammatory process due to statisti-
cally significant values (p<0.005, χ2=0.397). The increase in the level of transaminases (TGO and 
TGP) in the unvaccinated group proved a poor prognosis due to a more serious and lasting evolution 
of rotavirus infection (p>0.026). 
4. Determination of circulating genotypes (G4, G9, G3) by molecular biology techniques in the infant 
population proved and confirmed the usefulness of the Rotarix vaccine included in the National Im-
munization Calendar, manifested by a considerably lower morbidity of gastroenteritis of rotavirus 
etiology in the group of vaccinated children. 
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